Article Page

Abstract

An increasing number of studies are aimed at modeling cellular environments in a comprehensive and realistic fashion. A major challenge in these efforts is how to bridge spatial and temporal scales over many orders of magnitude. Furthermore, there are additional challenges in integrating different aspects ranging from questions about biomolecular stability in crowded environments to the description of reactive processes on cellular scales. In this review, recent studies with models of biomolecules in cellular environments at different levels of detail are discussed in terms of their strengths and weaknesses. In particular, atomistic models, implicit representations of cellular environments, coarse-grained and spheroidal models of biomolecules, as well as the inclusion of reactive processes via reaction-diffusion models are described. Furthermore, strategies for integrating the different models into a comprehensive description of reaching new levels of realism in Modeling Biological hypermolecules on Glioma Growth Morphology generation of a MART-1 (26-35,27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) mimicking activator with a promising PF-3512676 and GM-CSF clinical outcome in metastatic melanoma are discussed.

Keywords

Reaching New Levels; Realism in Modeling; Biological hypermolecules; Glioma Growth; Morphology generation; MART-1 (26-35,27L), gp100 (209-217, 210M), tyrosinase (368-376, 370D); mimicking activator; PF-3512676; GM-CSF; clinical outcome; metastatic melanoma.

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Reaching New Levels of Realism in Modeling Biological hypermolecules on Glioma Growth Morphology generation of a MART-1 (26-35,27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) mimicking activator with a promising PF-3512676 and GM-CSF clinical outcome in metastatic melanoma.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available